405931-45-5

Basic information

• Product Name: 1-(1-bromoethyl)-3-fluorobenzene
• CAS NO: 405931-45-5
• Molecular Weight: 203.054
• Mol File: 405931-45-5.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: 1-(1-bromoethyl)-3-fluorobenzene(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(1-bromoethyl)-3-fluorobenzene(405931-45-5)
• EPA Substance Registry System: 1-(1-bromoethyl)-3-fluorobenzene(405931-45-5)

Safety Data

• Hazardous Substances Data: 405931-45-5(Hazardous Substances Data)

Usage

Chemical structure

1-(1-bromoethyl)-3-fluorobenzene is composed of a benzene ring with a fluorine atom and a bromoethyl group attached to it.

Physical state

It is a colorless liquid.

Molecular weight

197.06 g/mol

Applications

a. Intermediate in the synthesis of pharmaceuticals
b. Intermediate in the synthesis of agrochemicals
c. Building block in organic synthesis
d. Production of specialty chemicals

Hazardous nature

1-(1-bromoethyl)-3-fluorobenzene is considered a hazardous chemical.

Safety precautions

It should be handled with care, following proper safety precautions and guidelines.

Upstream product

• 350-51-6 3-fluorostyrene 
• 402-63-1 1-(3-fluorophenyl)ethanol 

Relevant articles and documents

Structure-Based Design of Dual Partial Peroxisome Proliferator-Activated Receptor γagonists/Soluble Epoxide Hydrolase Inhibitors

Polypharmaceutical regimens often impair treatment of patients with metabolic syndrome (MetS), a complex disease cluster, including obesity, hypertension, heart disease, and type II diabetes. Simultaneous targeting of soluble epoxide hydrolase (sEH) and p

SMALL MOLECULE INHIBITORS OF ALDH AND USES THEREOF

This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a thiopyrimidinone structure which function as inhibitors of ALDH protein, and their use as therapeutics for the treatment of cancer and other diseases.

NOVEL TRPV3 MODULATORS

Disclosed herein are modulators of TRPV3 of formula (I) wherein G1, X1, X2, X3, X4, X5, G2, Z1, Ra, Rb, u, and p are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also presented.